Hennion & Walsh Asset Management Inc. Grows Stock Holdings in Johnson & Johnson $JNJ

Hennion & Walsh Asset Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 19.1% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 38,754 shares of the company’s stock after acquiring an additional 6,203 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Johnson & Johnson were worth $7,186,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Arcataur Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 15.1% in the 3rd quarter. Arcataur Capital Management LLC now owns 4,205 shares of the company’s stock valued at $780,000 after acquiring an additional 553 shares during the last quarter. Community Trust & Investment Co. increased its stake in Johnson & Johnson by 3.2% during the third quarter. Community Trust & Investment Co. now owns 5,561 shares of the company’s stock worth $1,031,000 after acquiring an additional 173 shares during the last quarter. Forza Wealth Management LLC raised its position in Johnson & Johnson by 2.6% during the third quarter. Forza Wealth Management LLC now owns 9,849 shares of the company’s stock valued at $1,826,000 after purchasing an additional 245 shares during the period. Gries Financial LLC lifted its stake in shares of Johnson & Johnson by 1.1% in the 3rd quarter. Gries Financial LLC now owns 19,653 shares of the company’s stock valued at $3,644,000 after purchasing an additional 223 shares during the last quarter. Finally, Madrona Financial Services LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter worth approximately $238,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Nipocalimab phase II success — JNJ reported nipocalimab met key endpoints in a Phase IIb SLE study, supporting a planned move to Phase III and de‑risking a late‑stage autoimmune program that could add future revenue. JNJ’s Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
• Positive Sentiment: MedTech growth catalyst — J&J MedTech submitted its Ottava surgical robot to the FDA, advancing a high‑margin growth avenue in robotics/surgery that could expand addressable market if cleared. Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Positive Sentiment: Research collaboration in cardiac gene therapy — JNJ is partnering with Lexeo Therapeutics to test localized AAV delivery using Impella technology, which could accelerate novel cardiac programs and strengthen cardiovascular R&D capabilities. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology
• Positive Sentiment: Analyst and media support — Barclays raised its JNJ price target (to $217) and Wolfe Research lifted its target to $240; high‑profile bullish commentary (Jim Cramer called it a “terrific entry point”) may attract buyers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs Wolfe Research Increases Johnson & Johnson Price Target to $240.00 Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”
• Neutral Sentiment: Innovative Medicines resilience — analysts note J&J’s Innovative Medicines segment remains resilient with key drugs offsetting some pressures; watch Q4 details for cadence and guidance. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch
• Neutral Sentiment: Macro tailwind for health care — sector rotation into health-care and dividend/value themes is supportive of JNJ stock but is a broader factor rather than company‑specific. Experts See Health Care’s Rally Continuing. This ETF Is Proof
• Negative Sentiment: Commercial headwinds — continued pressure from Stelara biosimilars and Medicare Part D dynamics could weigh on sales and near‑term margins in immunology/dermatology franchises. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on JNJ. Sanford C. Bernstein increased their price target on Johnson & Johnson from $172.00 to $193.00 and gave the company a “market perform” rating in a report on Monday, October 6th. HSBC reiterated a “buy” rating and set a $240.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, December 10th. Barclays raised their target price on shares of Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 30th. The Goldman Sachs Group upped their price target on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Finally, Stifel Nicolaus increased their price objective on shares of Johnson & Johnson from $165.00 to $190.00 and gave the stock a “hold” rating in a research report on Wednesday, October 15th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $212.62.

Johnson & Johnson Trading Down 0.8%

NYSE JNJ opened at $205.78 on Friday. The stock has a market cap of $495.79 billion, a PE ratio of 19.86, a PEG ratio of 2.13 and a beta of 0.34. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $215.18. The company’s 50-day moving average price is $202.56 and its 200-day moving average price is $184.15. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The firm had revenue of $24.02 billion during the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities research analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio is presently 50.19%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.